Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PsiOxus Therapeutics Ltd.

Division of Psioxus Therapeutics Ltd.
www.psioxus.com

Latest From PsiOxus Therapeutics Ltd.

PsiOxus Will Seek $50m Series D Financing In H1 2018 To Fund Pipeline

PsiOxus Therapeutics' CEO tells Scrip it will seek the fresh funding next year to progress its pipeline which aims to treat solid tumors through systemic delivery of oncolytic viruses.

Financing Deals

Touchstone Plays Tough As IP Group Ups Bid To £490m

One of the key attractions is Touchstone's holdings in Imperial College spin-offs such as Cell Medica, Circassia Pharmaceuticals and TopiVert Pharma.

M & A Intellectual Property

BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight

Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.

ImmunoOncology Business Strategies

Can Drugs Really Treat Sarcopenia? Some Patients Are Doubtful

Companies developing treatments for sarcopenia ‘have no idea what they're doing’, according to Ray Lipicky, a former director of the FDA’s Cardio-Renal Drug Products Division who spoke as a patient at the US agency’s sarcopenia drug development meeting.

Regulation Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Transgenics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Psioxus Therapeutics Ltd.
  • Senior Management
  • John Beadle, MD, CEO
    Theodora Harold, CFO & Secretary
    Hilary McElwaine-Johnn, MD, CMO
    Charles Morris, Chief Dev. Officer
    Karen LaRochelle, CBO
  • Contact Info
  • PsiOxus Therapeutics Ltd.
    Phone: (44) 1235 835328
    154B Brook Dr., Milton Park
    Abingdon
    Oxfordshire, OX14 4SD
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register